239 related articles for article (PubMed ID: 31267367)
1. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
[TBL] [Abstract][Full Text] [Related]
2. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection.
Zoulim F; Lenz O; Vandenbossche JJ; Talloen W; Verbinnen T; Moscalu I; Streinu-Cercel A; Bourgeois S; Buti M; Crespo J; Manuel Pascasio J; Sarrazin C; Vanwolleghem T; Shukla U; Fry J; Yogaratnam JZ
Gastroenterology; 2020 Aug; 159(2):521-533.e9. PubMed ID: 32343960
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.
Kakuda TN; Yogaratnam JZ; Westland C; Gane EJ; Schwabe C; Vuong J; Patel M; Snoeys J; Talloen W; Lenz O; Fry J; Chanda S; van Remoortere P
Antivir Ther; 2021; 26(1-2):13-24. PubMed ID: 35485346
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
5. A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers.
Zhao N; Jia B; Zhao H; Xu J; Sheng X; Luo L; Huang Z; Wang X; Ren Q; Zhang Y; Zhao X; Cui Y
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636065
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
Li C; Wu M; Zhang H; Mai J; Yang L; Ding Y; Niu J; Mao J; Wu W; Zhang D; Tang Y; Yan W
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0122021. PubMed ID: 34280012
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men.
Manitpisitkul P; Mayorga A; Shalayda K; De Meulder M; Romano G; Jun C; Moyer JA
Clin Drug Investig; 2015 Jun; 35(6):353-63. PubMed ID: 25894894
[TBL] [Abstract][Full Text] [Related]
8. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection.
Gane EJ; Schwabe C; Berliba E; Tangkijvanich P; Jucov A; Ghicavii N; Verbinnen T; Lenz O; Talloen W; Kakuda TN; Westland C; Patel M; Yogaratnam JZ; Dragone L; Van Remoortere P
J Antimicrob Chemother; 2022 Mar; 77(4):1102-1110. PubMed ID: 35040959
[TBL] [Abstract][Full Text] [Related]
9. JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B.
Gane E; Yuen MF; Kakuda TN; Ogawa T; Takahashi Y; Goeyvaerts N; Lonjon-Domanec I; Vaughan T; Schluep T; Hamilton J; Njumbe Ediage E; Hillewaert V; Snoeys J; Lenz O; Talloen W; Biermer M
Antivir Ther; 2022 Jun; 27(3):13596535221093856. PubMed ID: 35695169
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379.
Berke JM; Dehertogh P; Vergauwen K; Mostmans W; Vandyck K; Raboisson P; Pauwels F
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094138
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
Yuen MF; Gane EJ; Kim DJ; Weilert F; Yuen Chan HL; Lalezari J; Hwang SG; Nguyen T; Flores O; Hartman G; Liaw S; Lenz O; Kakuda TN; Talloen W; Schwabe C; Klumpp K; Brown N
Gastroenterology; 2019 Apr; 156(5):1392-1403.e7. PubMed ID: 30625297
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
Ackaert O; Vanhoutte F; Verpoorten N; Buelens A; Lachau-Durand S; Lammens L; Hoetelmans R; Van Loock M; Herrera-Taracena G
Clin Infect Dis; 2023 Sep; 77(6):857-865. PubMed ID: 37161721
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
Huntjens DRH; Ouwerkerk-Mahadevan S; Brochot A; Rusch S; Stevens M; Verloes R
Clin Pharmacokinet; 2017 Nov; 56(11):1331-1342. PubMed ID: 28238203
[TBL] [Abstract][Full Text] [Related]
14. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants.
Feng S; Gane E; Schwabe C; Zhu M; Triyatni M; Zhou J; Bo Q; Jin Y
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839221
[TBL] [Abstract][Full Text] [Related]
15. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
Kakuda TN; Yogaratnam J; Rito J; Boyce M; Mitchell T; Gupta K; Symons JA; Chanda S; Van Remoortere P; Fry J
Antivir Ther; 2018; 23(7):555-566. PubMed ID: 29927386
[TBL] [Abstract][Full Text] [Related]
16. Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy.
Verbinnen T; Hodari M; Talloen W; Berke JM; Blue D; Yogaratnam J; Vandenbossche J; Shukla U; De Meyer S; Lenz O
J Viral Hepat; 2020 Nov; 27(11):1127-1137. PubMed ID: 32579776
[TBL] [Abstract][Full Text] [Related]
17. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.
Lahlali T; Berke JM; Vergauwen K; Foca A; Vandyck K; Pauwels F; Zoulim F; Durantel D
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012770
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants.
Li H; Niu X; Zhang Y; Zhang D; Zhang Y; Wang L; Miao Y; Jiang Y; Ji J; Chen Q; Wu X; Ediage EN; Kakuda TN; Biermer M
Clin Pharmacol Drug Dev; 2023 Feb; 12(2):175-180. PubMed ID: 36415122
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
[TBL] [Abstract][Full Text] [Related]
20. EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B.
Feld JJ; Lawitz E; Nguyen T; Lalezari J; Hassanein T; Martin P; Han SH; Dieterich D; Giard JM; De La Rosa G; Ahmad A; Luo E; Conery AL; Adda N
Antivir Ther; 2022 Dec; 27(6):13596535221127848. PubMed ID: 36382358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
